sorafenib has been researched along with Cancer of Ovary in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (10.00) | 29.6817 |
2010's | 23 (76.67) | 24.3611 |
2020's | 4 (13.33) | 2.80 |
Authors | Studies |
---|---|
Abu-Sini, H; Billan, S; Taha, T | 1 |
Chen, S; Feng, R; Hu, Y; Li, J; Li, M; Li, X; Li, Z; Liao, X; Mo, S; Qian, W; Tang, M; Xie, C; Xu, Y; Yu, R; Yuan, S; Zhang, S | 1 |
An, D; Annunziata, CM; Cao, L; Chen, H; Choyke, P; Hays, JL; Kohn, EC; Lee, JM; Minasian, LM; Steinberg, SM; Turkbey, IB; Wright, J; Yu, M | 1 |
Feng, Y; Fu, Y; Guo, G; Guo, W; Hou, H; Huang, C; Jiang, C; Kuang, Y; Li, H; Li, X; Mu, M; Tong, A; Wang, J; Wang, Y; Wang, Z; Xu, J; Yang, C; Yang, H; Zhang, Z; Zhao, S; Zhou, L | 1 |
Duan, P; Fan, L; Gao, Q; Qu, W; Ren, M; Shen, Y; Silwal, BM | 1 |
Kim, D; Ko, HS; Park, GB | 1 |
Corrado, G; Ferrandina, G | 1 |
Braicu, EI; Chekerov, R; De Gregorio, N; du Bois, A; El-Balat, A; Fridrich, C; Harter, P; Hilpert, F; Krabisch, P; Lorenz, R; Lueck, HJ; Mahner, S; Markmann, S; Oskay-Oezcelik, G; Potenberg, J; Richter, R; Schmidt, M; Sehouli, J | 1 |
Colombo, N; Herzog, TJ; Kim, BG; Lhommé, C; Markowska, J; Oza, A; Petrenciuc, O; Ray-Coquard, I; Scambia, G; Sehouli, J; Shan, M | 1 |
Ferrero, S; Leone Roberti Maggiore, U; Valenzano Menada, M; Venturini, PL | 1 |
Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y | 1 |
Dent, P | 1 |
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
Haybaeck, J; Petru, E; Smolle, E; Taucher, V | 1 |
Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC | 1 |
Devapatla, B; Sharma, A; Woo, S | 1 |
Booth, L; Carter, J; Dent, P; McGuire, WP; Poklepovic, A; Roberts, JL; Webb, T | 1 |
Chen, TC; Chen, YC; Chien, CC; Lee, YC; Wu, MS; Yu, MC | 1 |
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ | 1 |
Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
Brüning, A; Burger, P; Burges, A; Friese, K; Gingelmaier, A; Vogel, M | 1 |
Annunziata, CM; Azad, N; Houston, N; Kohn, EC; Kotz, H; Lee, JM; Minasian, L; Sarosy, GA; Squires, J | 1 |
Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M | 1 |
Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ | 1 |
Baba, T; Hamanishi, J; Kang, HS; Konishi, I; Mandai, M; Matsui, S; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S | 1 |
Birrer, MJ; Bristow, RE; Calvert, V; Cohn, D; DeGeest, K; Farley, J; Lankes, HA; Matei, D; Mutch, D; Petricoin, EF; Sill, MW; Yamada, SD | 1 |
Bodnar, L; Górnas, M; Szczylik, C | 1 |
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C | 1 |
Annunziata, CM; Azad, NS; Chow, C; Kohn, EC; Kotz, HL; Minasian, L; Premkumar, A; Steinberg, SM | 1 |
3 review(s) available for sorafenib and Cancer of Ovary
Article | Year |
---|---|
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Topics: Angiogenesis Inhibitors; Bevacizumab; Clinical Trials as Topic; Female; Humans; Indazoles; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
Sorafenib for ovarian cancer.
Topics: Animals; Antineoplastic Agents; Female; Humans; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progression; Epithelial-Mesenchymal Transition; Female; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2014 |
12 trial(s) available for sorafenib and Cancer of Ovary
Article | Year |
---|---|
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Interleukin-8; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib | 2020 |
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Germany; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2018 |
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Sorafenib | 2013 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan | 2011 |
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; CA-125 Antigen; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pilot Projects; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Reproducibility of Results; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
15 other study(ies) available for sorafenib and Cancer of Ovary
Article | Year |
---|---|
Tyrosine kinase inhibitor treatment and long-term follow-up for metastatic malignant struma ovarii.
Topics: Adolescent; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Ovarian Neoplasms; Protein Kinase Inhibitors; Sorafenib; Struma Ovarii; Thyroid Neoplasms | 2022 |
SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Topics: Breast Neoplasms; Carcinoma, Hepatocellular; Fatty Acid Transport Proteins; Fatty Acids; Fatty Acids, Unsaturated; Female; Ferroptosis; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Topics: Animals; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; B7 Antigens; Carcinoma, Ovarian Epithelial; CD3 Complex; Cell Line, Tumor; Cell Proliferation; Datasets as Topic; Drug Synergism; Female; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Sorafenib; T-Lymphocytes; Xenograft Model Antitumor Assays | 2020 |
Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Topics: Basigin; Cell Line, Tumor; Cell Movement; Down-Regulation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Hyaluronan Synthases; Hyaluronic Acid; MAP Kinase Signaling System; Neoplasm Invasiveness; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib | 2017 |
Treatment of platinum refractory or resistant ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan | 2018 |
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Multi-kinase inhibition in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Inhibitory Concentration 50; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Phenylurea Compounds; Sildenafil Citrate; Sorafenib | 2015 |
Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Female; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species; Sorafenib | 2016 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Phosphorylation; Propidium; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2010 |
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Gene Expression Profiling; Humans; Mice; Mice, Nude; Niacinamide; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2010 |